Patents by Inventor Yanan GUO

Yanan GUO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Genetically modified non-human animal with human or chimeric CD137
    Patent number: 11154040
    Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD137, and methods of use thereof.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: October 26, 2021
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yuelei Shen, Yanan Guo, Yang Bai, Lei Zhao, Rui Huang, Jiawei Yao, Meiling Zhang
  • Anti-PD-1 antibodies and uses thereof
    Patent number: 11155625
    Abstract: This disclosure relates to anti-PD-1 (Programmed Cell Death Protein 1) antibodies, antigen-binding fragments, and the uses thereof.
    Type: Grant
    Filed: July 2, 2020
    Date of Patent: October 26, 2021
    Assignee: Eucure (Beijing) Biopharma Co., Ltd
    Inventors: Yi Yang, Jingshu Xie, Chunyan Dong, Fang Yang, Chengyuan Lu, Xiaodong Cheng, Yuelei Shen, Jian Ni, Yanan Guo, Yunyun Chen
  • Fault identifying method for sludge bulking based on a recurrent RBF neural network
    Patent number: 11144816
    Abstract: The wastewater treatment process by using activated sludge process often appear the sludge bulking fault phenomenon. Due to production conditions of wastewater treatment process, the correlation and restriction between variables, the characteristics of nonlinear and time-varying, which lead to hard identification of sludge bulking; Sludge bulking is not easy to detect and the reasons resulting in the sludge bulking are difficult to identify, are current RBF neural network is designed for detecting and identifying the causes of sludge volume index (SVI) in this patent. The method builds soft-computing model of SVI based on recurrent RBF neural network, it has been completed to the real-time prediction of SVI concentration and better accuracy were obtained. Once the fault of sludge bulking is detected, the identifying cause variables (CVI) algorithm can find the cause variables of sludge bulking.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: October 12, 2021
    Assignee: BEIJING UNIVERSITY OF TECHNOLOGY
    Inventors: Honggui Han, Yanan Guo, Junfei Qiao
  • Anti-CD40 antibodies and uses thereof
    Patent number: 11142582
    Abstract: This disclosure relates to anti-CD40 (TNF Receptor Superfamily Member 5) antibodies, antigen-binding fragments, and the uses thereof.
    Type: Grant
    Filed: January 14, 2021
    Date of Patent: October 12, 2021
    Assignee: Eucure (Beijing) Biopharma Co., Ltd
    Inventors: Yi Yang, Chunyan Dong, Fang Yang, Chengyuan Lu, Yuelei Shen, Jian Ni, Yanan Guo, Yunyun Chen, Jingshu Xie
  • ANTI-PD-1 ANTIBODIES AND USES THEREOF
    Publication number: 20210284735
    Abstract: This disclosure relates to anti-PD-1 (Programmed Cell Death Protein 1) antibodies, antigen-binding fragments, and the uses thereof.
    Type: Application
    Filed: May 19, 2021
    Publication date: September 16, 2021
    Inventors: Yi Yang, Chunyan Dong, Fang Yang, Chengyuan Lu, Yuelei Shen, Jian Ni, Yanan Guo, Yunyun Chen, Jingshu Xie
  • ANTI-CD3e ANTIBODIES AND USES THEREOF
    Publication number: 20210269525
    Abstract: This disclosure relates to anti-CD3e (T-cell surface glycoprotein CD3 epsilon chain) antibodies, antigen-binding fragments, and the uses thereof.
    Type: Application
    Filed: June 19, 2019
    Publication date: September 2, 2021
    Inventors: Yi Yang, Yunyun Chen, Jingshu Xie, Chunyan Dong, Fang Yang, Chengyuan Lu, Xiaodong Cheng, Yuelei Shen, Jian Ni, Yanan Guo
  • GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD3e
    Publication number: 20210259220
    Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD3e (T-cell surface glycoprotein CD3 epsilon chain), and methods of use thereof.
    Type: Application
    Filed: February 5, 2021
    Publication date: August 26, 2021
    Inventors: Yuelei Shen, Yanan Guo, Rui Huang, Xiaofei Zhou, Yang Bai, Jiawei Yao, Chaoshe Guo
  • Method of using a genetically modified mouse that expresses a humanized CTLA-4 gene
    Patent number: 11096383
    Abstract: The present disclosure relates to the genetically modified non-human animals that express a human or chimeric CTLA-4, and methods of use thereof.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: August 24, 2021
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yuelei Shen, Yanan Guo, Yang Bai, Jiawei Yao, Chengzhang Shang, Rui Huang
  • Genetically modified non-human animal with human or chimeric CTLA-4
    Patent number: 11071290
    Abstract: The present disclosure relates to the genetically modified non-human animals that express a human or chimeric CTLA-4, and methods of use thereof.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: July 27, 2021
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yuelei Shen, Yanan Guo, Yang Bai, Jiawei Yao, Chengzhang Shang, Rui Huang
  • ANTI-TNFRSF9 ANTIBODIES AND USES THEREOF
    Publication number: 20210206867
    Abstract: This disclosure relates to anti-TNFRSF9 (tumor necrosis factor receptor superfamily member 9) antibodies, antigen-binding fragments, and the uses thereof.
    Type: Application
    Filed: March 12, 2021
    Publication date: July 8, 2021
    Inventors: Yi Yang, Jingshu Xie, Chunyan Dong, Fang Yang, Chengyuan Lu, Yuelei Shen, Jian Ni, Yanan Guo, Yunyun Chen
  • ANTI-OX40 ANTIBODIES AND USES THEREOF
    Publication number: 20210206866
    Abstract: This disclosure relates to anti-OX40 (TNF Receptor Superfamily Member 4, or TNFRSF4) antibodies, antigen-binding fragments, and the uses thereof.
    Type: Application
    Filed: January 5, 2021
    Publication date: July 8, 2021
    Inventors: Yi Yang, Yanan Guo, Yunyun Chen, Jingshu Xie, Chunyan Dong, Fang Yang, Chengyuan Lu, Xiaodong Cheng, Yuelei Shen, Jian Ni
  • ANTI-CTLA4 ANTIBODIES AND USES THEREOF
    Publication number: 20210188981
    Abstract: This disclosure relates to anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4 or CTLA-4) antibodies, antigen-binding fragments, and the uses thereof.
    Type: Application
    Filed: February 22, 2021
    Publication date: June 24, 2021
    Inventors: Yi Yang, Yanan Guo, Xiaodong Cheng, Yunyun Chen, Jingshu Xie, Chunyan Dong, Fang Yang, Chengyuan Lu, Yuelei Shen, Jian Ni
  • Anti-CTLA4 antibodies and uses thereof
    Patent number: 11034764
    Abstract: This disclosure relates to anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4 or CTLA-4) antibodies, antigen-binding fragments, and the uses thereof.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: June 15, 2021
    Assignee: Eucure (Beijing) Biopharma Co., Ltd
    Inventors: Yi Yang, Yanan Guo, Xiaodong Cheng, Yunyun Chen, Jingshu Xie, Chunyan Dong, Fang Yang, Chengyuan Lu, Yuelei Shen, Jian Ni
  • ANTI-CD40 ANTIBODIES AND USES THEREOF
    Publication number: 20210155705
    Abstract: This disclosure relates to anti-CD40 (TNF Receptor Superfamily Member 5) antibodies, antigen-binding fragments, and the uses thereof.
    Type: Application
    Filed: January 14, 2021
    Publication date: May 27, 2021
    Inventors: Yi Yang, Chunyan Dong, Fang Yang, Chengyuan Lu, Yuelei Shen, Jian Ni, Yanan Guo, Yunyun Chen, Jingshu Xie
  • Anti-CTLA4 antibodies and uses thereof
    Patent number: 11001632
    Abstract: This disclosure relates to anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4 or CTLA-4) antibodies, antigen-binding fragments, and the uses thereof.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: May 11, 2021
    Assignee: Eucure (Beijing) Biopharma Co., Ltd
    Inventors: Yi Yang, Yanan Guo, Xiaodong Cheng, Yunyun Chen, Jingshu Xie, Chunyan Dong, Fang Yang, Chengyuan Lu, Yuelei Shen, Jian Ni
  • GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD47
    Publication number: 20210120790
    Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD47, and methods of use thereof.
    Type: Application
    Filed: November 2, 2020
    Publication date: April 29, 2021
    Inventors: Yuelei Shen, Yang Bai, Jian Ni, Rui Huang, Chengzhang Shang, Yanan Guo
  • Genetically modified non-human animal with human or chimeric CD27
    Patent number: 10980222
    Abstract: The present disclosure relates to genetically modified non-human animals (e.g., genetically-modified mice) that express a human or chimeric (e.g., humanized) CD27. The present disclosure also relates to methods of generating the genetically-modified animals (e.g., genetically modified mice), and methods of using the genetically modified non-human animals (e.g., genetically modified mice) described herein.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: April 20, 2021
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yuelei Shen, Yang Bai, Rui Huang, Chengzhang Shang, Yanan Guo, Meiling Zhang
  • IMMUNODEFICIENT NON-HUMAN ANIMAL
    Publication number: 20210105982
    Abstract: The present disclosure relates to the genetically modified non-human animals that have a disruption at the endogenous CD132 gene (e.g.
    Type: Application
    Filed: September 24, 2020
    Publication date: April 15, 2021
    Inventors: Yuelei Shen, Yang Bai, Meiling Zhang, Jiawei Yao, Rui Huang, Yanan Guo
  • Genetically modified non-human animal with human or chimeric SIRPa
    Patent number: 10973212
    Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) SIRP?, and methods of use thereof.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: April 13, 2021
    Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
    Inventors: Yuelei Shen, Yang Bai, Meiling Zhang, Rui Huang, Chengzhang Shang, Yanan Guo
  • Genetically modified non-human animal with human or chimeric CD3e
    Patent number: 10945420
    Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD3e (T-cell surface glycoprotein CD3 epsilon chain), and methods of use thereof.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: March 16, 2021
    Assignees: BiocytogenPharmaceuticals (Beijing) Co., Ltd., Biocytogen JiangSu Co., Ltd.
    Inventors: Yuelei Shen, Yanan Guo, Rui Huang, Xiaofei Zhou, Yang Bai, Jiawei Yao, Chaoshe Guo